ImmuPharma (LON:IMM) Shares Down 31.4% – Should You Sell?

by · The Cerbat Gem

Shares of ImmuPharma plc (LON:IMM – Get Free Report) fell 31.4% during mid-day trading on Monday . The stock traded as low as GBX 6.70 and last traded at GBX 6.70. 27,337,178 shares changed hands during mid-day trading, an increase of 242% from the average session volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.

ImmuPharma Stock Up 8.8%

The company has a 50-day moving average of GBX 10.72 and a 200 day moving average of GBX 5.88. The stock has a market capitalization of £37.20 million, a PE ratio of -8.31 and a beta of 1.53.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Read More